Batı Nil Virüs Enfeksiyonu

Öz Batı Nil Virusu (BNV) kanatlılar, atlar, insanlar ve diğer memeli hayvanlarda nöropatik hastalıklara neden olan, eklem bacaklılarla (arhtropotlarla) nakledildiği için arbovirus olarak tanımlanan Arthropod Borne virus sınıfındadır. Doğal yaşam döngüsü Culex cinsi sivrisinekler ile evcil ve yabani kuşlar arasında olan etkenin, atlar başta olmak üzere insanlar ve diğer memeliler düşük viremi seviyesi ile rastlantısal konaklarıdır. Özellikle son yıllarda baraj göllerinin artması ve sulu tarım yapılan alanların yaygınlaşması sonucu, sokucu sinek popülasyonlarındaki artışa bağlı olarak bunlar aracılığı ile aktarılan çeşitli insan ve hayvan enfeksiyonlarındaki artış dikkat çekici boyutlara ulaşmıştır. Yapılan bu derlemede insan ve hayvan sağlığı açısından önemli olan BNV enfeksiyonu ile ilgili bilgiler verilmiştir.

Kaynakça

1. Alpert SG, Fergerson J, Noel LP, (2003). Intrauterine West Nile virus: ocular and systemicfindings. Am J Ophthalmol. 136, 733-735.

2. Anderson JF, Rahal JJ, (2002). Efficacy of interferon alpha- 2b and ribavirin against West Nile virus in vitro. Emerging infectious diseases. 8(1), 107-108.

3. Bagnarelli P, Marinelli K, Trotta D, Monachetti A, Tavio M, Del Gobbo R, Capobianchi MR, Menzo S, Nicoletti L, Magurano F, Varaldo PE, (2011). Human case of autochthonous West Nile virus lineage 2 infection in Italy, September 2011. Euro Surveill. 16(43), 1-4.

4. Bakır E, (2015). Batı Nil Virüsü Varlığının Marmara Bölgesi Kan Donörlerinde Serolojik Ve Moleküler Yöntemler İle Araştırılması. Yüksek Lisans Tezi, İstanbul Üniversitesi Cerrahpaşa Tıp Fakültesi Tıbbi Mikrobiyoloji ABD ve Tıbbi Viroloji Bilim Dalı, İstanbul.

5. Bakonyi T, Hubalek Z, Rudolf I, Nowotny N, (2005). Novel flavivirus or new lineage of West Nile virus, central Europe. Emerg. Infect. Dis. 11(2), 225-231.

6. Bakonyi T, Ivanics E, Erdelyi K, Ursu K, Ferenczi E, Weissenbock H, Nowotny N, (2006). Lineage 1 and 2 strains of encephalitic West Nile virus, central Europe. Emerg. Infect. Dis. 12(4), 618-623.

7. Ben-Nathan D, Gershoni-Yahalom O, Samina I, Khinich Y, Nur I, Laub O,Gottreich A, Simanov M, Porgador A, Zisman BR, Orr N, (2009). Using high titer West Nile intravenous immunoglobulin from selected Israeli donors for treatment of West Nile virus infection. BMC infectious diseases. 9, 18.

8. Biendenbender R, Bevilacqua J, Gregg AM, Watson M, Dayan G, (2011). Phase II, randomized, double-bling, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virüs vaccine in healthy adults. J Infect Dis. 203, 75-84.

9. Blut A, (2013). West Nile Virus. Transfus Med Hemother. 40, 265-284.

10. Bogachek MV, Zaitsev BN, Sekatskii SK, Protopopova EV, Ternovoi VA, Ivanova AV, Kachko AV, Ivanisenko VA, Dietler G, Loktev VB, (2010). Characterization of glycoprotein E C-end of West Nilevirus and evaluation of its interaction force with alphaVbeta3 integrin asputative cellular receptor. Biochemistry. 75, 472-480.

11. Bondre VP, Jadi RS, Mishra AC, Yergolkar PN, Arankalle VA, (2007). West Nile virus isolates from India: evidence for a distinct genetic lineage. J. Gen. Virol. 88, 875-884.

12. Brington MA, (2014). Replication Cycle and Molecular Biology of the West Nile Virus, Viruses. 6, 13-53.

13. Bulaşıcı Hastalıklar Sürveyans ve Kontrol Esasları YönetmeliğindeDeğişiklik Yapılmasına Dair Yönetmelik. Resmi Gazete; 02.04.2011 - 27893. http://www.resmigazete. gov.tr/eskiler/2011/04/20110402-3.htm Erişim tarihi: 23.05.2016.

14. Bunning LM, Bowen AR, Cropp B, Sullivan GK, David SB, Komar N, Godsey SM, BakerD, Hettler LD, Holmes AD, Biggerstaff JB, Mitchell JC, (2002). Experimental infection ofhorses with west nile virus. Emerg Inf Dis. 8(4), 380-386.

15. Busch MR, Kleinman SH, Tobler LH, Kamel HT, Norris PJ, Walsh I, Matud JL, Prince HE, Lanciotti RS, Wright DJ, Linnen JM, Caglioti S, (2008). Virus and antibody dynamics in acute West Nile virüs infection. J. Infect. Dis. 198, 984-993.

16. Byrne SN, Halliday GM, Johnston LJ, King NJC, (2001). Interleukin-1beta but not tumornecrosis factor is involved in West Nile virus-induced Langerhans cell migration from the skin in C57BL/6 mice. 117(3), 702-709.

17. CDC, (2011). Expert consultation on West Nile virus infection. Thessaloniki, ECDC, 25-26 January

18. CDC, (2013). West Nile Virus in the UnitedStates: Guidelines for Surveillance, Prevention, and Control, 4th Revision June 14.

19. Chan-Tack KM, Forrest G, (2005). Failure of interferon alpha- 2b in a patient with West Nile virus meningoencephalitis and acute flaccid paralysis. Scand J Infect Dis. 37, 944-6.

20. Charatan F, (2002). Organ transplants and blood transfusions may transmit West Nile virus. BMJ. 14, 325(7364)- 566.

21. Colpitts TM, Conway MJ, Montgomery RR, Fikrig E, (2012). West Nile Virus: Biology, Transmission, and Human Infection. Clin Microbiol Rev. 25, 635-648.

22. Cunha BA, (1999). West Nile Encephalitis. Infectious Disease Practice for Clinicians. 23(10), 85-89.

23. Dauphin G, Zientara S, (2007). West Nile virus: Recent trends in diagnosis andvaccine development. Vaccine. 25, 5563- 5576.

24. Debiasi RL, (2011). West Nile virus neuroinvasive disease. Curr Infect Dis Rep. 13(4), 350-359.

25. Diamond SM, (2003). Evasion of innate and adaptive immunite by flavivirus. Immunol and Cell Biol. 81, 196-206.

26. Duran B, Chevalier V, Pouillot R, Labie J, Marendat I, Murgue B, Zeller H, Zientara S, (2002). West nile virus outbreak in horses, Southern France, 2000: Results of serosurvey. Emerg Infect Dis. 8(8), 777-782.

27. Erdem H, Pahsa A, (2003). Yeni bir pandemi mi ? Batı Nil virüs enfeksiyonu. İnfeksiyon Dergisi. 17, 245-249.

28. Ergünay K, (2010). Batı Nil Virusu: Viroloji, Epidemiyoloji ve Mikrobiyolojik Tanı. III Türkiye Zoonotik Hastalıklar Sempozyumu; Ankara.

29. Ergünay K, Aydoğan S, Menemenlioğlu D, (2010). Ankara Bölgesinde Nedeni Bilinmeyen Merkezi Sinir Sistemi Enfeksiyonlarında Batı Nil Virüsünün Araştırılması. Mikrobiyol Bul. 44, 255-262.

30. Ertürk A, (2010). Batı Nil virüsü enfeksiyonunda korunma ve kontrol. III Türkiye Zoonotik Hastalıklar Sempozyumu. 166- 173.

31. Gyure KA, (2009). West Nile virus infections. J. Neuropath. Exp. Neur. 68, 1053-1060.

32. Hall RA, Khromykh AA, (2004). West Nile virus vaccines. Expert Opin Biol Ther. 4, 1295-1305.

33. Hayes EB, Sejvar JJ, Zaki SR, Lanciotti RS, Bode AV, Campbell GL, Lanciotti RS, Bode AV, Campbell GL, (2005). Virology, pathology and clinical manifestations of West Nile virus disease. Emerg. Infect. Dis. 11, 1174-1179.

34. Heinz FX, Collett MS, Purcell RH, Gould EA, Howard CR, Houghton M,Moormann RJM, Rice CM, Thiel HJ, (2000). Family: Flaviviridae. Ed(s) Van Regenmortel MHV, Fauquet CM,Bishop DHL, Carstens EB, Estes MK, Lemon SM, et al. eds. Virustaxonomy: classification and nomenclature of viruses. 7th Report of theInternational Committee on Taxonomy of Viruses. San Diego, Academic Press, p. 859-878.

35. Hızel K, Yenicesu İ, Erdal B, Yeşilyurt E, Fidan I, Kalkancı A, Dilsiz G, (2010). Investigation of West Nile virus seroprevalence in healthy blood donors. Mikrobiyol. Bul. 44, 425-430.

36. Huhn GD, Sejvar JJ, Montgomery SP, Dworkin MS, (2003). West Nile virus in theUnited States: an update on an emerging infectious disease. Am Fam Physician. 68, 653-660.

37. Jordan I, Briese T, Fischer N, Lau JY, Lipkin WI, (2000). Ribavirin inhibits West Nile virus replication and cytopathic effect in neural cells. The Journal of infectious diseases. 182(4), 1214-1217.

38. Kalaycıoğlu H, (2010). Türkiye’de görülen West Nile vakalarının epidemiyolojisi. III. Türkiye Zoonotik Hastalıklar Sempozyumu, Ankara, Türkiye, 1-2 Kasım 2010, 174-183.

39. Kalaycioglu H, Korukluoglu G, Ozkul A, Oncul O, Tosun S, Karabay O, Gozalan A, Uyar Y, Caglayık DY, Atasoylu G, Altas AB, Yolbakan S, Ozden TN, Bayrakdar F, Sezak N, Pelıtlı TS, Kurtcebe ZO, Aydın E, Ertek M, (2012). Emergence of West Nile virüs infection in humnas in Turkey, 2010 to 2011. Eurosurveillance. 17, p. 20182.

40. Kılıç A, Doğancı L, (2003). Batı Nil Virus. Türk Mikrobiyoloji Cemiyeti Dergisi. 33, 284-290.

41. Komar N, Langevin S, Hinten S, Nemeth N, Edwards E, Hettler DL, Davis BS, Bowen RA, Bunning ML, (2003). Experimental infection of North American birds with the New York 1999 strain of West Nile virus. Emerg. Infect. Dis. 9(3), 311-322.

42. Lanciotti SR, Kerst JA, Nasci SR, Godsey MS, Mitchell CJ, Savage HM, Komar N, Panella NA, Allen BC, Volpe KE, Davis BS, Roehrig JT, (2000). Rapid detection of West Nile Virus from human clinical specimens, field-collected mosquitoes, and avian samples by a TaqMan reverse transcriptase- PCR assay. J Clin Microbiol. 38, 4066-4071.

43. Lewis M, Amsden JR, (2007). Successful treatment of West Nile virus infection after approximately 3 weeks into the disease course. Pharmacotherapy. 27, 455-458.

44. Lim P-Y, Behr MJ, Chadwick CM, Shi P-Y, Bernard KA, (2011). Keratinocytes are cell targets of west nile virus in vivo. J. Virol. 85(10), 5197-5201.

45. Lim SM, Koraka P, Osterhaus AD, Martina BE, (2011). West Nile virus: immunity and pathogenesis. Viruses. 3(6), 811- 828.

46. Lindenbach BD, Thiel HJ, Rice CM, (2007). Flaviviridae. In Fields virology, vol 1,5th ed. In Knipe DM, Howley PM, eds. (Lippincott Williams & Wilkins:Philadelphia). p. 1101-1113.

47. Lindenbach BD, Murray CI, Thiel HJ, Rice CM, (2013). Flaviviridae. Fields Virology, 6th Ed. In Knipe DM, Howley PM, eds. (Lippincott Williams & Wilkins, Philadelphia). p. 712-746.

48. Lindsey NP, Staples JE, Lehman JA, Fischer M, (2010). Centers for Disease Control and Prevention (CDC). Surveillance for human West Nile virus disease - United States, 1999-2008. MMWR Surveill Summ. 59, 1-17.

49. Lvov DK, Butenko AM, Gromashevsky VL, Kovtunov AI, Prilipov AG, Kinney R, Aristova VA, Dzharkenov AF, Samokhvalov EI, Savage HM, Shchelkanov MY, Galkina IV, Deryabin PG, Gubler DJ, Kulikova LN, Alkhovsky SK, Moskvina TM, Zlobina LV, Sadykova GK, Shatalov AG, Lvov DN, Usachev VE, Voronina AG, (2004). West Nile virus and other zoonotic viruses in Russia: examples of emergingre emergingsituations. Arch Virol Suppl. 18, 85-96.

50. Mackenzie JS, Williams DT, (2009). The zoonotic flaviviruses of southern, south-easternand eastern Asia, and Australasia: the potential for emergent viruses. Zoonoses Public Health. 56(6-7), 338-356.

51. Marfin AA, Gubler DJ, (2001). West Nile encephalitis: an emerging disease in the United States. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 33(10), 1713-1719.

52. May FJ, Davis CT, Tesh RB, Barrett ADT, (2011). Phylogeography of West Nile virus: from the cradle of evolution in Africa to Eurasia, Australia, and the Americas. J Virol. 85(6), 2964-2974.

53. Meço O, (1975). Güney Doğu Anadolu ve Doğu Karadeniz Bölgeleri Halkında Arbovirus Hemaglütinasyon-İnhibisyon Antikorlarının Araştırılması. Doçentlik Tezi, Ankara Üniversitesi Tıp Fakültesi, Ankara.

54. Meço O, (1977). Güneydoğu Anadolu halkında Batı Nil ateşi hemaglütinasyon önlenim antikorlarının araştırılması. Mikrobiyol. Bul. 11, 3-17.

55. Monath PT, Heinz XF, (1996). Flaviviruses. In: Pields NB, Knipe DM, Howley MP, Chanock RM, Melnick LJ, Monath PT, Poizman B, Strauss ES. Field’s Virology, 3 rdedition, Philedelphia, Lippincott-Raven. p. 961-1034.

56. Monath TP, Liu J, Kanesa-Thasan N, Myers GA, Nichols R, Deary A,McCarthy K, Johnson C, Ermak T, Shin S, Arroyo J, Guirakhoo F, Kennedy JS, Ennis FA, Green S, Bedford P, (2006). A live, attenuated recombinant West Nile virus vaccine. Proc Natl Acad Sci USA. 103, 6694-6699.

57. Monini M, Falcone E, Busani L, Romi R, Ruggeri FM, (2010). West Nile virus: Characteristics of an African virus adapting to the third millennium world. Open Virol. J. 22, 42-51.

58. Murgue B, Murri S, Triki H, (2001). West Nile in the Mediterranean basin: 1950-2000. Ann NY Acad Sci. 951, 117-126.

59. Murray KO, Mertens E, Despres P, (2010). West Nile virus and its emergence in the United States of America. Vet Res. 41, 67.

60. Murray KO, Walker C, Gould E, (2011). The virology, epidemiology, and clinicalimpact of West Nile virus: A decade of advancements in resarch since itsintroduction into Western Hemisphere. Epidemiol Infect. 139, 807-817.

61. Nosal B, Pellizzari R, (2003). West Nile Virus. CMAJ. 168, 1443-1444.

62.O’Leary DR, Marfin AA, Montgomery SP, Kipp AM, Lehman JA, Biggerstaff BJ, Elko VL, Collins PD, Jones JE, Campbell GL, (2004). The epidemic of West Nile virus in the United States. Vector Borne Zoonotic Dis. 4, 61-70.

63. Ozkul Aykut, Ergunay Koray, Koysuren Aydan, Alkan Feray, Arsava Ethem M., Tezcan Seda, Emekdas Gurol, Hacioglu Sabri, Turan Mahur, Us Durdal, (2013). Concurrent occurrence of human and equine West Nile virus infections in Central Anatolia, Turkey: the first evidence for circulation of lineage 1 viruses. International Journal of Infectious Diseases 17, 546-551

64. Petersen LR, Brault AC, Nasci RS, (2013). West Nile Virus: Review of the Literature. JAMA. 310(3), 308-315.

65. Petersen LR, Marfin AA, (2002). West Nile Virus: A primer for the clinician. Ann Intern Med. 137, 173-179.

66. Pierson TC, Diamond MS, (2012). Degrees of maturity : the complex structure andbiology of flaviviruses. Curr Opin Virol. 2, 168-175.

67. Pletnev AG, Claire MS, Elkins R, Speicher J, Murphy BR, Chanock RM, (2003). Molecularly engineered live-attenuated chimeric West Nile/dengue virus vaccines protect rhesus monkeys from West Nile virus. Virology. 314, 190-195.

68. Reiter P, (2010). West Nile virus in Europe: understanding the present to gauge the future. Euro Surveill. 15, 19508.

69. Rossi S, Ross TM, Evans JD, (2010). West Nile virus. Clin. Lab. Med. 30, 47-65.

70. Sampath A, Padmanabhan R, (2009). Molecular targets for flavivirus drug discovery. Antiviral Res. 81, 6-15.

71. Sampathkumar P, (2003). West Nile Virus: Epidemiology, clinical presentation, diagnosis and prevention. Mayo Clin. Proc. 78, 1137-1144.

72. Samuel MA, Diamond MS, (2006). Pathogenesis of West Nile virus infection: abalance between virulence, innate and adaptive immunity, and viral evasion. J Virol. 80, 9349-9360.

73. Sanchez MD, Pierson TC, McAllister D, Hanna SL, Puffer BA, ValentineLE, Murtadha MM, Hoxie JA, Doms RW, (2005). Characterization of neutralizing antibodies to West Nile virus. Virology. 336(1), 70-82.

74. Savini G, Capelli G, Monaco F, Polci A, Russo F, Di Gennaro A,Marini V, Teodori L, Montarsi F, Pinoni C, Pisciella M, Terregino C, Marangon S, Capua I,Lelli R, (2012). Evidence of West Nile virus lineage 2 circulation in northern Italy. Vet. Microbiol. Aug 17. 158(3-4), 267-273.

75. Shi PY, Kramer LD, (2003). Molecular detection of West Nile virus RNA. Expert Review of Molecular Diagnostics.n3, 357- 366.

76. Shimoni Z, Niven MJ, Pitlick S, Bulvik S, (2001). Treatment of West Nile virus encephalitis with intravenous immunoglobulin. Emerging infectious diseases. 7(4), 759.

77. Smithburn K, Hughes T, Burke AA, (1940). neurotropic virus isolated from theblood of a native of Uganda. Am J Trop Med. 20, 471-492.

78. Spohn G, Jennings GT, Martina BE, Keller I, Beck M, Pumpens P,Osterhaus AD, Bachmann MF, (2010). A VLPbased vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice. Virol J. 7, 146.

79. Taylor RM, Work TH, Hurlbut HS, (1956). A study of the ecology of West Nilevirus in Egypt. Am J Trop Med. 5, 579-62013.

80. Tezcan S, Ülger M, Emekdaş G, (2011). Batı Nil Virusu ve infeksiyonu. Mersin Üniv Sağlık Bilim Derg. 4(3), 9-17

81. Tosun S, (2010). Batı Nil virüsü enfeksiyonunda klinik ve tedavi. III. Türkiye Zoonotik Hastalıklar Sempozyumu, Ankara, Türkiye, 1-2 Kasım 2010, 161-165.

82. Weiss D, Carr D, Kellachan J, Tan C, Phillips M, Bresnitz E,Layton M, and West Nile Virus Outbreak Response Working Group (2001). Clinical findings of West Nile Virus infection in hospitalized patients, New York and New Jersey 2000. Emerg Infect.Dis. 7, 654-659.

83. www.cvma.net/publications/press-releases/west-nile-virusin- dogs-cats/ Erişim Tarihi: 25.10.2016.

84. Yazıcı Z, (2005). Batı Nil Virusu infeksiyonu. İnfeksiyon Dergisi (Turkish Journal of Infection). 19 (1), 139-143.

Kaynak Göster

APA Dinç, E , Yıldırım, Y . (2016). Batı Nil Virüs Enfeksiyonu . Etlik Veteriner Mikrobiyoloji Dergisi , 27 (2) , 139-148 . DOI: 10.35864/evmd.515971